Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for... – Lyase
Reexamination Certificate
1997-09-29
2002-07-23
Achutamurthy, Ponnathapu (Department: 1652)
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Lyase
C435S320100, C435S325000, C435S006120, C536S023100, C536S023200, C536S023500
Reexamination Certificate
active
06423527
ABSTRACT:
TECHNICAL FIELD
The present invention relates generally to cancer detection and therapy. The invention is more particularly related to springiness-1-phosphate lease polynucleotides and polypeptides, and to agents that modulate the expression and/or activity of such polypeptides. Such agents may be used, for example, to diagnose and/or treat cancers such as breast cancer.
BACKGROUND OF THE INVENTION
Breast cancer is a significant health problem for women in the United States and throughout the world. Although advances have been made in detection and treatment of the disease, breast cancer remains the most common form of cancer, and the second leading cause of cancer death, in American women. Among African-American women and women between 15 and 54 years of age, breast cancer is the leading cause of cancer death. One out of every eight women in the United States will develop breast cancer, a risk which has increased 52% during 1950-1990. In 1994, it is estimated that 182,000 new cases of female breast cancer were diagnosed, and 46,000 women died from the disease.
No vaccine or other universally successful method for the prevention or treatment of breast cancer is currently available. Management of the disease currently relies on a combination of early diagnosis (through routine breast screening procedures) and aggressive treatment, which may include one or more of a variety of treatments such as surgery, radiotherapy, chemotherapy and hormone therapy. The course of treatment for a particular breast cancer is often selected based on a variety of prognostic parameters, including an analysis of specific tumor markers. However, the use of established markers often leads to a result that is difficult to interpret.
With current therapies, tumor invasiveness and metastasis is a critical determinant in the outcome for breast cancer patients. Although the five year survival for women diagnosed with localized breast cancer is about 90%, the five year survival drops to 18% for women whose disease has metastasized. Present therapies are inadequate for inhibiting tumor invasiveness for the large population of women with this severe disease.
Accordingly, improvements are needed in the treatment, diagnosis and prevention of breast cancer. The present invention fulfills this need and further provides other related advantages.
SUMMARY OF THE INVENTION
Briefly stated, the present invention provides compositions and methods for the diagnosis and therapy of cancer. Within one aspect, the present invention provides isolated polynucleotides comprising a sequence selected from the group consisting of: (a) a sequence recited in SEQ ID NO:1; (b) a sequence recited in SEQ ID NO:3; (c) nucleotide sequences that hybridize to a polynucleotide complementary to either of the foregoing sequences under moderately stringent conditions, wherein the nucleotide sequences encode polypeptides having springiness-1-phosphate lease activity; and (d) nucleotide sequences that encode a polypeptide encoded by any of the foregoing sequences.
Within a related aspect, an isolated polynucleotide is provided that encodes a polypeptide recited in SEQ ID NO:2, or a variant of such a polypeptide that has springiness-1-phosphate lease activity. In another related aspect, an isolated polynucleotide comprising a sequence recited in SEQ ID NO:4, or a variant of such a polypeptide that has springiness-1-phosphate lease activity, is provided.
Recombinant expression vectors comprising any of the foregoing polynucleotides, and host cells transformed or transfected with such expression vectors, are also provided.
Within further aspects, SPL polypeptides are provided. Such polypeptides may be encoded by any of the foregoing polynucleotides. Alternatively, a polypeptide may comprise an amino acid sequence recited in SEQ ID NO:2 or 4, or a variant thereof, wherein the polypeptide has springiness-1-phosphate lease activity.
Within a further aspect, the present invention provides isolated polynucleotides comprising at least 100 nucleotides complementary to a sequence recited in SEQ ID NO:1 or 3.
Within other aspects, methods are provided for preparing a springiness-1-phosphate lease, comprising culturing a host cell transformed or transfected with a polynucleotide as described above under conditions promoting expression of the polynucleotide and recovering a springiness-1-phosphate lease.
In further aspects, the present invention provides methods for identifying an agent that modulates springiness-1-phosphate lease activity. In one such aspect, the method comprises: (a) contacting a candidate agent with cells that express springiness-1-phosphate lease; and (b) subsequently measuring the level of springiness-1-phosphate lease or mRNA encoding springiness-1-phosphate lease in the cells, relative to a predetermined level in the absence of candidate agent. Within another such aspect, the method comprises: (a) contacting a candidate agent with a polypeptide comprising a sequence recited in any one of SEQ ID NOs: 2, 4, 6 or 8, or a variant of such a sequence having springiness-1-phosphate lease activity, wherein the step of contacting is carried out under conditions and for a time sufficient to allow the candidate modulator to interact with the polypeptide; and (b) subsequently measuring the ability of the polypeptide to degrade springiness-1-phosphate or a derivative thereof, relative to an ability in the absence of candidate agent. The step of contacting may be performed by incubating a cell expressing the polypeptide with the candidate modulator, and the step of measuring the ability to degrade springiness-1-phosphate may be performed using an in vitro assay and a cellular extract.
The present invention further provides pharmaceutical compositions comprising an agent that modulates springiness-1-phosphate lease activity in combination with a pharmaceutically acceptable carrier. Such agents preferably inhibit springiness-1-phosphate lease activity. Such inhibition may be achieved by inhibiting expression of an endogenous SPL gene, or by inhibiting the ability of an endogenous SPL to degrade springiness-1-phosphate. Within certain preferred embodiments, a modulating agent comprises a polynucleotide or an antibody or an antigen-binding fragment thereof.
Within still further aspects, the present invention provides methods for modulating springiness-1-phosphate activity, comprising contacting a springiness-1-phosphate lease with an effective amount of an agent that modulates springiness-1-phosphate lease activity, wherein the step of contacting is performed under conditions and for a time sufficient to allow the agent and the springiness-1-phosphate lease to interact. To modulate springiness-1-phosphate lease activity in a cell, a cell expressing springiness-1-phosphate may be contacted with such an agent.
Within related aspects, the present invention provides methods for inhibiting the growth of a cancer cell, comprising contacting a cancer cell with an agent that inhibits springiness-1-phosphate lease activity. In a preferred embodiment, the cancer cell is a breast cancer cell.
The present invention also provides methods for inhibiting the development and/or metastasis of a cancer in a mammal, comprising administering to a mammal an agent that inhibits springiness-1-phosphate lease activity. Within certain embodiments, an agent may comprise, or be linked to, a targeting component, such as an anti-tumor antibody or a component that binds to an estrogen receptor.
Within other aspects, methods for diagnosing cancer in a mammal are provided, comprising detecting an alteration in an endogenous springiness-1-phosphate lease gene in a sample obtained from a mammal, and therefrom diagnosing a cancer in the mammal. In certain embodiments the cancer is breast cancer and the sample is a breast tumor biopsy.
In related aspects, the present invention provides methods for evaluating a cancer prognosis, comprising determining the presence or absence of an alteration in an endogenous springiness-1-phosphate lease gene in a sample obtained from a mammal afflicted wi
Saba Julie D.
Zhou Jianhui
Achutamurthy Ponnathapu
Children's Hospital Medical Center of Northern California
Seed IP Law Group PLLC
Tung Peter P.
LandOfFree
Sphingosine-1-phosphate lyase polypeptides, polynucleotides... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sphingosine-1-phosphate lyase polypeptides, polynucleotides..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sphingosine-1-phosphate lyase polypeptides, polynucleotides... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2891081